文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

长链非编码 RNA FOXD2-AS1 作为竞争性内源性 RNA 对抗 miR-150-5p 逆转肝癌对索拉非尼的耐药性。

LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.

机构信息

Department of Special Treatment Ⅰ and Liver Transplantation, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China.

Department of Hepato-Pancreato-Biliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.

出版信息

J Cell Mol Med. 2019 Sep;23(9):6024-6033. doi: 10.1111/jcmm.14465. Epub 2019 Jun 18.

DOI:10.1111/jcmm.14465
PMID:31210410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6714507/
Abstract

The current study elucidated the role of a long non-coding RNA (lncRNA), FOXD2-AS1, in the pathogenesis of hepatocellular carcinoma (HCC) and the regulatory mechanism underlying FOXD2-AS1/miR-150-5p/transmembrane protein 9 (TMEM9) signalling in HCC. Microarray analysis was used for preliminary screening of candidate lncRNAs in HCC tissues. qRT-PCR and Western blot analyses were used to detect the expression of FOXD2-AS1. Cell proliferation assays, luciferase assay and RNA immunoprecipitation were performed to examine the mechanism by which FOXD2-AS1 mediates sorafenib resistance in HCC cells. FOXD2-AS1 and TMEM9 were significantly decreased and miR-150-5p was increased in SR-HepG2 and SR-HUH7 cells compared with control parental cells. Overexpression of FOXD2-AS1 increased TMEM9 expression and overcame the resistance of SR-HepG2 and SR-HUH7 cells. Conversely, knockdown of FOXD2-AS1 decreased TMEM9 expression and increased the sensitivity of HepG2 and Huh7 cells to sorafenib. Our data also demonstrated that FOXD2-AS1 functioned as a sponge for miR-150-5p to modulate TMEM9 expression. Taken together, our findings revealed that FOXD2-AS1 is an important regulator of TMEM9 and contributed to sorafenib resistance. Thus, FOXD2-AS1 may serve as a therapeutic target against sorafenib resistance in HCC.

摘要

本研究阐明了长链非编码 RNA (lncRNA) FOXD2-AS1 在肝细胞癌 (HCC) 发病机制中的作用，以及 FOXD2-AS1/miR-150-5p/跨膜蛋白 9 (TMEM9) 信号在 HCC 中的调控机制。芯片分析用于初步筛选 HCC 组织中的候选 lncRNA。qRT-PCR 和 Western blot 分析用于检测 FOXD2-AS1 的表达。细胞增殖实验、荧光素酶实验和 RNA 免疫沉淀实验用于研究 FOXD2-AS1 介导 HCC 细胞索拉非尼耐药的机制。与对照亲本细胞相比，SR-HepG2 和 SR-HUH7 细胞中 FOXD2-AS1 和 TMEM9 显著降低，miR-150-5p 升高。FOXD2-AS1 的过表达增加了 TMEM9 的表达，并克服了 SR-HepG2 和 SR-HUH7 细胞的耐药性。相反，FOXD2-AS1 的敲低降低了 TMEM9 的表达，增加了 HepG2 和 Huh7 细胞对索拉非尼的敏感性。我们的数据还表明，FOXD2-AS1 作为 miR-150-5p 的海绵体发挥作用，调节 TMEM9 的表达。总之，我们的研究结果表明，FOXD2-AS1 是 TMEM9 的重要调节因子，参与索拉非尼耐药。因此，FOXD2-AS1 可能成为 HCC 索拉非尼耐药的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/30f99a3dfa64/JCMM-23-6024-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/74893562fca4/JCMM-23-6024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/7ce633d20735/JCMM-23-6024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/58c12510136e/JCMM-23-6024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/704a9bb03529/JCMM-23-6024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/d6161056a97d/JCMM-23-6024-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/30f99a3dfa64/JCMM-23-6024-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/74893562fca4/JCMM-23-6024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/7ce633d20735/JCMM-23-6024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/58c12510136e/JCMM-23-6024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/704a9bb03529/JCMM-23-6024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/d6161056a97d/JCMM-23-6024-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/630b/6714507/30f99a3dfa64/JCMM-23-6024-g006.jpg

相似文献

[1]
LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.

J Cell Mol Med. 2019-6-18

[2]
LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.

Biomed Pharmacother. 2021-1

[3]
Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.

J Cell Biochem. 2021-1

[4]
Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by mA methylation promotes disease progression and sorafenib resistance.

Hum Cell. 2021-11

[5]
LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.

J Cell Mol Med. 2018-3-30

[6]
LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.

J Exp Clin Cancer Res. 2019-5-3

[7]
A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.

Mol Cancer. 2019-2-19

[8]
Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p.

J Cell Mol Med. 2020-1

[9]
lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.

J Cell Biochem. 2021-1

[10]
Long Noncoding RNA (lncRNA) FOXD2-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Regulating MiR-185/AKT Axis.

Med Sci Monit. 2019-12-16

引用本文的文献

[1]
Long non-coding RNAs and autophagy: dual drivers of Hepatocellular carcinoma progression.

Cell Death Discov. 2025-8-11

[2]
The Emerging Role of Long Noncoding RNAs in Sorafenib Resistance Within Hepatocellular Carcinoma.

Cancers (Basel). 2024-11-21

[3]
LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis.

Naunyn Schmiedebergs Arch Pharmacol. 2024-12-16

[4]
A disulfidptosis-related lncRNA signature for analyzing tumor microenvironment and clinical prognosis in hepatocellular carcinoma.

Front Immunol. 2024

[5]
Advances in hepatocellular carcinoma drug resistance models.

Front Med (Lausanne). 2024-7-31

[6]
TMEM9 promotes lung adenocarcinoma progression via activating the MEK/ERK/STAT3 pathway to induce VEGF expression.

Cell Death Dis. 2024-4-25

[7]
The role of competing endogenous RNA network in the development of hepatocellular carcinoma: potential therapeutic targets.

Front Cell Dev Biol. 2024-1-31

[8]
miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma.

Noncoding RNA Res. 2023-10-24

[9]
Bioinformatics prediction and experimental verification identify cuproptosis-related lncRNA as prognosis biomarkers of hepatocellular carcinoma.

Biochem Biophys Rep. 2023-6-21

[10]
The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma.

Int J Mol Sci. 2023-2-1

本文引用的文献

[1]
The functional pathway analysis and clinical significance of miR-20a and its related lncRNAs in breast cancer.

Cell Signal. 2018-8-6

[2]
Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance.

J Cell Mol Med. 2018-7-4

[3]
Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.

Biomed Pharmacother. 2018-4-24

[4]
PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers.

Nat Commun. 2018-2-28

[5]
Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer.

Mol Cancer. 2017-11-21

[6]
Microarray data re-annotation reveals specific lncRNAs and their potential functions in non-small cell lung cancer subtypes.

Mol Med Rep. 2017-8-14

[7]
Effects of TMEM9 gene on cell progression in hepatocellular carcinoma by RNA interference.

Oncol Rep. 2016-7

[8]
DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression.

Cancer Res. 2016-2-1

[9]
STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7.

Cancer Cell Int. 2015-11-26

[10]
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.

Mol Cancer. 2015-9-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索